Multiple contract wins ensure solid results for life sciences business
York-based Aptamer Group, which develops molecular binders called aptamers as an alternative to antibodies, has reported a 152% revenue rise in its full year results for the 12 months ended 30 June 2022.
Revenues for the period increased to £4m (15-month period to 30 June 2021: £1.6m), while the life sciences company also recorded an adjusted EBITDA loss of £1.7m (15-month period to 30 June 2021: £2.4m).
The pre-tax loss for the year was £2.6m (2021: £2.9m pre-tax loss) and the group raised gross proceeds of £10.8m in conjunction with its AIM listing on 22 December 2021.
Arron Tolley, chief executive officer, said: “Aptamer has maintained a solid pace of progress over the past year, having seen success in both expanding current partnerships and winning new contracts. Commercial traction continues to increase in Europe, USA and APAC regions.
“Looking ahead to the rest of the current financial year, we aim to continue delivering strong revenue growth and we expect to sign new contracts across all business units.
“This will demonstrate our progress and ability to capitalise on the clear market opportunity and demand for outsourcing the development of next-generation affinity ligands.
“Despite the challenging macro-economic environment, the first quarter of the current financial year has already seen the signing of several new contracts and we are on track to meet market expectations for the full year.”
This month, a planned relocation to larger 18,000 sq ft purpose-built laboratories was completed and this will allow Aptamer to scale its automation and operational efficiency and service the increasing demand for Optimer® binders.
